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tion of donor T cells into the lung. To examine the effect of these
chemokines on T cell recruitment, we treated allogeneic recipients
with polyclonal antibodies (Abs) against MIG and IP-10 or control
from day 0 until day 28. Lung pathology at day 28 was signiﬁcantly
decreased in the Ab-treated animals and was associated with sig-
niﬁcantly decreased numbers of total cells, CD8T cells and
TNFa levels in the BAL ﬂuid (table 1). MIG/IP-10 neutralization
also resulted in reduced damage to the GI tract by week 1 and 4
(table 1), whereas liver pathology was unaffected. Clinical GVHD
scores were also lower in Ab-treated animals at weeks 5 and 6 after
SCT and correlated with a reduction in mortality during this time.
In a ﬁnal set of experiments, we used CXCR3-/- mice as allo SCT
donors and found that mice receiving CXCR3-/- cells had de-
creased lung injury compared to allo wild-type controls at week 4
as measured by BAL cellularity (1.2  0.1 vs. 2.5  0.4 mio),
CD8T cells (0.06  0.01 vs. 0.17  0.03 mio) and TNFa levels
(9.0  1.8 vs. 33.4  8.0 pg/ml). In conclusion, our data demon-
strate, that interactions between the chemokines MIG and IP-10
and their receptor CXCR3 are important for donor T cell recruit-
ment into the lung and the development of IPS. Approaches
focusing on the abrogation of these interactions may prove suc-
cessful in preventing or treating this serious complication after
allogeneic SCT.
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DONOR LEUKOCYTE-PRODUCTION OF RANTES SIGNIFICANTLY CON-
TRIBUTES TO THE DEVELOPMENT OF IDIOPATHIC PNEUMONIA SYN-
DROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Hildebrandt, G.C.1, Olkiewicz, K.M.1, Corrion, L.C.1, Liu, C.2, Cooke,
K.R.1 1. Dept. of Pediatrics; BMT Program, University of Michigan,
Ann Arbor, MI; 2. Dept. of Pathology; University of Florida School of
Medicine, Gainesville, FL
Idiopathic pneumonia syndrome (IPS) is a major cause of mor-
tality after allogeneic (allo) stem cell transplantation (SCT). IPS
pathophysiology includes the secretion of inﬂammatory cyto- and
chemokines along with the recruitment of donor T cells and
monocytes/macrophages. We hypothesized that leukocyte recruit-
ment during IPS is dependent, at least in part, upon interactions
between RANTES and its primary receptor CCR5: RANTES is
produced predominantly by CD8 T cells, epithelium, and ﬁbro-
blasts and promotes CCR5 T cell and macrophage inﬁltration to
inﬂammatory sites. Using an established mouse SCT model, le-
thally irradiated B6DF1 mice received SCT from syngeneic
(B6D2F1) or allogeneic (B6) donors. Pulmonary CCR5 mRNA
expression was signiﬁcantly increased from week 1 to week 6 in allo
SCT recipients compared to syngeneic controls and correlated
with donor effector cell recruitment to the lung and increasing
histopathology scores over time. Pulmonary RANTES mRNA
expression was signiﬁcantly increased from week 1 to 6 after allo
SCT and correlated with increases in BAL ﬂuid protein levels at
weeks 2 (277.7  21.2 vs 18.2  18.2 pg/ml) and 6 (103.3  40.1
vs 0.8  0.8 pg/ml). Furthermore, percentages of RANTES se-
creting CD4 and CD8 T cells were signiﬁcantly increased in
lungs of allo SCT recipients by week 2 after transplant (CD4:
14.8  5.5 vs 0.7  0.2; CD8: 17.2  5.9 vs 0.6  0.2). This
suggested that RANTES production from donor effector cells
contributes to the evolution of IPS. We next used wild type (wt) or
RANTES-/- mice as allo SCT donors. Lung injury after RAN-
TES-/- SCT was signiﬁcantly reduced by week 6 compared to wt
controls and was associated with decreases in total BAL cellularity
and in numbers of CD8 and CD4 T cells (Table 1). Although
survival (wt: 54% vs RANTES-/-: 66%) and clinical GVHD score
(wt: 4.8  0.4 vs RANTES-/-: 4.1  0.4) were not different
between groups, injury to GI tract and liver was decreased after
RANTES-/- SCT (Table 1). We next completed mixing experi-
ments wherein wt or RANTES-/- bone marrow was supplemented
with either wt or RANTES-/- T cells and found that RANTES
from both cellular sources contributes to IPS. Collectively, these
data demonstrate that RANTES production by donor leukocytes is
important to the development of lung, intestinal and hepatic dam-
age after allo SCT and suggest that strategies which disrupt
RANTES:CCR5 interactions may be helpful in treating or pre-
venting IPS and target organ GVHD.
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ANTIBODY RESPONSE TO H-Y MINOR HISTOCOMPATIBILITY ANTI-
GENS CORRELATES WITH CHRONIC GRAFT VERSUS HOST DISEASE AND
DISEASE REMISSION
Miklos, D.B., Kim, H.T., Miller, K.H., Guo, L., Zorn, E., Hochberg,
E.P., Lee, S.J., Soiffer, R.J., Antin, J.H., Ritz, J. Dana-Farber Cancer
Institute, Boston, MA
H-Y antigens are important targets of graft versus host disease
(GVHD) and graft versus leukemia in male patients who receive
hematopoietic stem cell transplants from female donors (F 3 M
HSCT). In previous studies, we demonstrated that male patients
who receive stem cells from female donors (F 3 M HSCT)
frequently develop antibody responses to H-Y antigen DBY. To
determine whether other Y-chromosome encoded proteins elicit
B-cell immune responses in F 3 M HSCT, we developed ELISA
for 5 H- Y antigens: DBY, UTY, ZFY, RPS4Y and EIF1AY and
their respective X-homologues. Serum samples from 125 HSCT
patients and 136 normal donors were tested (Table below). Over-
all, 51% of male patients with female donors developed antibody to
at least 1 H-Y antigen compared to 18% with antibody to any H-X
homolog (p  0.001). All H-X responders were also H-Y respond-
ers, and the magnitude of each H-Y response was greater than the
corresponding H-X response. Normal males and M 3 M HSCT
patients rarely had antibody detected for any H-Y antigen, how-
ever 41% of females had antibody detected for at least one H-Y
antigen. F3MHSCT serial samples revealed: 1) antibody to H-Y
antigens were absent pre-HSCT, 2) DBY antibody developed 4-8
months post-HSCT either concurrently or before UTY, ZFY, and
RPS4Y antibodies, and 3) each H-Y antibody response persisted
for at least two years post-HSCT. In order to explore the clinical
signiﬁcance of B-cell response to H-Y antigens, we measured 66
well-characterized F3MHSCT patients six months to two years
post-HSCT with our novel ﬁve H-Y antigens ELISA panel and
correlated these results with clinical outcome. The overall inci-
dence of limited or extensive cGVHD in this cohort was 53%. The
presence of an antibody response to 1 or more H-Y antigens was
highly signiﬁcantly correlated with the development of cGVHD
(p  0.001), and persistent disease remission (p  0.001). Logistic
regression models examining donor age, patient age, unrelated
donor, HLA-mismatched donor, stem cell source, disease, T cell
depletion, or nonmyeloablative conditioning failed to establish
association of these risk factors with either cGVHD or H-Y sero-
Table.
Lung
Path.
Total
BAL
Cells
(mio.)
BAL CD8
Cells (mio.)
BAL
TNF
(pg/mL)
Gut
Path.
Week 1
Gut Path.
Week 4
Synctrl 1.40.4 0.60.04 0.040.003 6.90.1 8.00.6 13.01.0
Alloctrl 5.30.4 1.60.38 0.190.047 20.83.2 23.21.6 19.52.3
Alloanti-
MIG/IP-
10 3.50.4* 0.40.04* 0.020.002* 7.83.0* 13.81.6* 13.21.6 ()
*P  .05; () P  .06.
Table.
Group
Lung
Path.
BAL
Cellularity
(mio.)
BAL
CD8
(mio.)
BAL
CD4
(mio.)
GI Tract
Path.
Liver
Path.
Syngeneic 0.2  0.1 0.7  0.3 0.01  0.01 0.1  0.1 4.6  0.8 1.6  0.3
Allo wt 5.3  0.6 2.5  0.2 0.7  0.1 0.5  0.1 14.0  0.8 14.1  1.0
Allo
RANTES/
2.5  0.5* 0.8  0.2* 0.3  0.1* 0.3  0.1 10.6  1.4* 8.6  0.7*
*P  .05.
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logic response. However, H-Y serologic response is strongly asso-
ciated with cGVHD in a multivariable logistic model (p  0.007).
These results support the hypothesis that B cell responses to H-Y
mHA play an important role in the pathogenesis of cGVHD and
suggests that anti-B cell therapy may be useful in the treatment of
this disease.
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CHARACTERIZATION OF THE TUMOR-SPECIFIC ACTIVITY OF WT1 SPE-
CIFIC T CELLS GENERATED IN VITRO FROM NORMAL INDIVIDUALS BY
SENSITIZATION WITH WT1-PEPTIDE LOADED AUTOLOGOUS EBV
TRANSFORMED B CELLS
Doubrovina, E.S., Doubrovin, M.M., Shieh, J.H., Bierwiaczonek, A.,
Heller, G., Pamer, E., O’Reilly, R.J. Memorial Sloan-Kettering Cancer
Center, New York, NY
The Wilms’ tumor protein WT1 is over-expressed in most acute
and chronic leukemias. Isolated T-cell clones have been reported
to recognize WT1 peptides binding by HLA-A0201 and HLA-
A2402 and lyse WT1 leukemic lines. To test WT1 peptide
immunogenicity in normal individuals, we sensitized T-cells from
9 HLA-A0201 and 4 HLA-A2402 donors with autologous EBV
transformed B cells (EBV-BLCL) or cytokine-activated monocytes
(CAM), loaded with HLA-A0201-binding WT1 peptides RMFP-
NAPYL or SLGEQQYSV or the HLA- A2402- binding WT1
peptide RVPGVAPTL. WT1-peptide speciﬁc cytotoxic and inter-
feron-gamma producing T-cells were generated from each donor.
T-cells sensitized with peptide-loaded EBV-BLCL generated
higher numbers of WT1 speciﬁc T-cells than peptide loaded
CAM. The frequencies of WT1 peptide-speciﬁc T-cells measured
by binding to peptide-HLA tetramers were similar to those gen-
erated against individual immunogenic HLA-A0201 binding EBV
peptides. These T-cells speciﬁcally lysed WT1 leukemias (n 
16) and solid tumors (n  12) in an HLA-restricted manner, but
neither lysed autologous or HLA-sharing normal CD34 hema-
topoietic progenitor cells (n  12) nor affected their yield of
CFU-GM, BFU-C or CFU-MIX. Following adoptive transfer into
SCID mice bearing subcutaneous xenografts of WT1 and WT1-,
HLA-A0201 leukemias, WT1-peptide-speciﬁc T-cells preferen-
tially accumulated in and induce regressions only of WT1 leu-
kemias . The long-term repeated in vivo scintigraphic imaging of
such T cells, transduced to express an HSV-TK/GFP fusion gene,
following intravenous infusions of the HSV-TK substrate [131I]-
FIAU demonstrated progressive accumulation of the T cells over a
period of 8 days in tumors, expressing targeted antigen and the
HLA restricting allele. These studies demonstrate that T cells
speciﬁc to the self antigen WT1 can be regularly generated from
normal individuals and that these cells exhibit signiﬁcant anti-
tumor activity both in vitro and in vivo. Such cells may prove useful
for adoptive therapy of leukemias in man.
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EX VIVO ACTIVATED AND EXPANDED CD8 T CELLS RECOGNIZE
MALIGNANT CELLS THROUGH A TCR INDEPENDENT AND NKG2D DE-
PENDENT PATHWAY
Verneris, M.R.1, Karami, M.2, Baker, J.2, Jasawal, A.1, Negrin, R.S.2
1. University of Minnesota, Minneapolis, MN; 2. Stanford University,
Stanford, CA
T cells that are activated by TCR crosslinking antibodies and
expanded with high doses of IL-2 attain cytotoxicity against ma-
lignant target cells without prior exposure or antigen priming. The
mechanism of this MHC-unrestricted cytotoxicity is unknown.
NKG2D is a cell surface receptor on both NK and CD8 T cells.
Here we examined ex vivo activated and expanded CD8 T cells to
determine if NKG2D plays a role in the recognition and triggering
of cytotoxicity against malignant targets. FACS analysis showed
that NKG2D could be detected on freshly isolated CD8 cells and
expression is increased after 21 days of culture. To access the
functional role of NKG2D on ex vivo activated and expanded
CD8 T cells we performed 51Cr release assays using NKG2D
blocking antibodies. Blocking NKG2D attenuated the killing of
malignant cell targets by 75%, while control antibodies had no
effect. Similarly, blocking NKG2D counter-ligands on malignant
targets attenuated cytotoxicity by 50-100%. To conﬁrm and ex-
tend these ﬁndings, we designed siRNA against NKG2D. 72 hours
after siRNA transfection, surface NKG2D was nearly undetect-
able, while other proteins (TCR or CD3) were unchanged. Cells
treated with NKG2D siRNA were not cytotoxic, while those
treated with control siRNA had cytotoxicity similar to non-trans-
fected cells. To determine whether NKG2D ligation alone trig-
gered cytotoxicity, we performed redirected killing assays using Fc
bearing murine target cells. Cells loaded with NKG2D antibodies,
but not isotype control antibodies, triggered cytotoxicity. To fur-
ther demonstrate NKG2D dependent, TCR independent target
recognition, we used FACS puriﬁed activated and expanded CD8
T cells and MHC class I def. targets which can not present peptide
antigen to CD8 T cells. Activated and expanded CD8 T cells
lysed these targets and blocking NKG2D nearly completely inhib-
ited cytolysis. Activated and expanded T cells acquire cytolytic
activity at day 10 of culture, in response to high (300 U/ml), but
not low (30 U/ml) concentrations of IL-2. DAP10 is the only
known adapter protein to transmit NKG2D signals in humans. We
therefore assayed for DAP10 at various time points in culture.
DAP10 was not detected until day 10, and only in response to high
doses of IL-2. Collectively, these studies show that activated and
expanded CD8 T cells recognize targets through a NKG2D
dependent, TCR independent pathway, likely controlled at the
level of DAP10 expression in response to IL-2.
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MODULATION OF TREG CELLS BY EXTRACORPOREAL PHOTOPHERESIS
IN CHRONIC GRAFT-VS-HOST DISEASE
Xie, M., Chan, G., Foss, F. Tufts New England Medical Center, Boston,
MA
While the pathogenesis of chronic graft-vs-host disease has not
been fully elucidated, alloreactive T cells, antigen presenting cells
(APC) and inﬂammatory cytokine secretion have been implicated.
Extracorporeal photopheresis (ECP) has demonstrated efﬁcacy in
patients with steroid-refractory acute and chronic GVHD. While
the mechanism of action of ECP in GVHD remains to be fully
deﬁned, we have demonstrated that clinical response in patients
with extensive, refractory cGVHD was associated with normaliza-
tion of skewed CD4/CD8 ratios and alterations in dendritic cell
and T-cell phenotypes, favoring a DC2/Th2 cytokine proﬁle.
These results suggest that ECP may indirectly or directly modulate
the function or activation of alloreactive T cells in GVHD. In an
attempt to determine the effects of ECP on T cell activation we
have examined the expression of negative co-stimulatory molecules
on T cells from cGVHD patients treated with ECP. We found
signiﬁcant changes in ICOS (inducible costimulatory molecule),
but not PD-l (programmed death gene 1) and CD137 (4-1BB) on
T cells during ECP treatment. Of 16 patients studied, we found
that clinical response to ECP was associated with an increase of
CD4ICOS cells. ICOS T-cells are a strong stimulator of
IL-10 production and Th2 differentiation, and we have previously
reported that ECP treatment is associated with an increase in
IL-10 production by T-helper cells in patients with cGVHD.
Populations of CD4CD25 cells have recently been identiﬁed as
immunoregulatory T cells (Treg), however a recent study of allo-
geneic stem cell grafts suggests that CD4/CD25 coexpression may
Table. Antibody Response to H-Y Antigens
H-Y
antigen: DBY UTY ZFY RPS4Y EIF1AY
>1
H-Y
>1
H-X
F3M
HSCT
34/79
(43%)
18/79
(23%)
17/79
(22%)
5/79
(6%)
5/79
(6%)
40/79
(51%)
14/79
(18%)
M3M
HSCT 0 0
4/46
(9%) 0 0
4/46
(9%)
6/46
(13%)
Normal
Females
11/70
(16%)
4/70
(6%)
3/70
(4%)
15/70
(21%)
9/70
(13%)
29/70
(41%)
12/70
(17%)
Normal
Males
1/64
(2%) 0 0
1/64
(2%)
3/64
(5%)%
5/64
(8%)
5/64
(8%)
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